Causes and Interpretation of False‑Low Fecal Elastase‑1 (FE‑1) Results

Primary Cause – Stool Consistency

Watery or liquid stools dilute fecal elastase‑1, making low FE‑1 results a common false‑positive for pancreatic exocrine insufficiency. 1
Accurate FE‑1 measurement requires semi‑solid or solid stool specimens; testing on liquid stool should be avoided. [1][2]

Duodenal diseases such as celiac disease and Crohn’s disease can lower FE‑1 values by disrupting enteric hormone release and intestinal‑pancreatic signaling. 1

A therapeutic trial of pancreatic enzymes does not reliably confirm exocrine pancreatic insufficiency and should not be used to validate a questionable low FE‑1 result. [1][3]
In the absence of high‑risk pancreatic conditions (chronic pancreatitis, pancreatic cancer, cystic fibrosis, or prior pancreatic surgery), a low FE‑1 result should raise suspicion for a false‑positive finding. 1

Step 1 – Stool Consistency: If the sample is watery/liquid, do not interpret the FE‑1 value; request a repeat specimen after the stool has become formed. 1
Step 4 – Clinical Risk Assessment:
- When high‑risk pancreatic conditions are present, a low FE‑1 is likely indicative of true exocrine pancreatic insufficiency. 1
- When no high‑risk conditions exist and FE‑1 is in the indeterminate range (100–200 µg/g), the result should be considered uncertain; repeat testing or alternative diagnostic approaches are recommended. 1

Damage to the duodenal mucosa reduces cholecystokinin‑mediated pancreatic secretion, resulting in lower fecal elastase‑1 concentrations despite intact pancreatic synthetic capacity. 4

Pancreatic ductal adenocarcinoma is classified as a high‑risk pancreatic condition in which a low fecal elastase‑1 result most likely reflects true exocrine pancreatic insufficiency. 4

Therapeutic trials of pancreatic enzyme replacement should not be used to validate a questionable low fecal elastase‑1 result, because such trials can mask underlying non‑pancreatic disorders (e.g., duodenal disease). 4
Repeating fecal elastase‑1 to monitor treatment response is discouraged; the test does not correlate with clinical improvement and is unaffected by exogenous enzyme therapy. 4

When suspicion for genuine pancreatic exocrine insufficiency remains high despite the presence of duodenal disease, a quantitative 72‑hour fecal fat test should be considered to confirm steatorrhea (defined as > 7 % fat malabsorption). 4